接触X线近距离放疗作为高危局部晚期直肠癌新辅助(放化疗)后的推量治疗
该研究基于328例直肠癌患者的风险分层,评估新辅助(放化疗)后肿瘤显著降期再行接触X线近距离放疗(CXB)推量的肿瘤学结局与耐受性。中位随访33个月,高危组较低/中危组远处复发率更高(21.2% vs 10.7%,P=0.01),但临床完全缓解、局部再生长、区域复发、3年器官保留、5年无病生存和总生存无显著差异,毒性可接受。作者认为CXB推量是经选择的高危直肠癌患者的可行选择。
要点
- 高危组远处复发率高于低/中危组(21.2% vs 10.7%,P=0.01)。
- 两组临床完全缓解、局部再生长、区域复发、器官保留及生存均无显著差异。
- 治疗时间较长、两次治疗间隔>24周及高于标准CXB剂量为新发现的负面因素。
核心结论
- 高危直肠癌患者接受CXB推量后远处复发较多,但局部区域肿瘤控制、器官保留、无病生存和总生存与较低危患者相当,毒性可接受。
- 作者认为CXB推量是经选择的高危直肠癌患者的可行选择。
- 作者指出及时再评估、及时转诊和CXB剂量优化对改善结局至关重要。
研究设计与样本
- 基于直肠癌治疗风险分层的328例患者评估肿瘤学结局与治疗耐受性。
- 低/中危定义为cT1-3ab、N0-1、M0、无壁外静脉侵犯、直肠系膜筋膜受累>1 mm。
- 高危定义为cT3cd-4/N2、M0、直肠系膜筋膜≤1 mm和/或壁外静脉侵犯阳性。
- 中位随访33个月(IQR 15-54),中位年龄73岁(IQR 62-80)。
主要发现
- 低/中危组与高危组临床完全缓解分别为78%与73%(P=0.32)。
- 低/中危组与高危组局部再生长分别为16.6%与22.4%(P=0.41)。
- 低/中危组与高危组淋巴结复发分别为1.8%与5.8%(P=0.051),区域复发分别为1.3%与2.9%(P=0.33)。
- 低/中危组与高危组远处复发分别为10.7%与21.2%(P=0.01),高危组较高。
- 低/中危组与高危组3年器官保留分别为87%与80%(P=0.25),5年无病生存分别为64%与62%(P=0.46),总生存分别为64%与67%(P=0.88);放疗后毒性P=0.16。
关键数值与推荐
- 较长治疗时间、两次治疗间隔>24周及给予高于标准CXB剂量为新发现的负面影响因素。
临床怎么用
- 作者认为CXB推量是经选择的高危直肠癌患者的可行选择。
- 作者指出及时再评估、及时转诊和CXB剂量优化对改善结局至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radical surgery following neoadjuvant therapy is the standard of care for locally advanced rectal cancer. A contact x-ray brachytherapy (CXB) boost can alternatively be used to treat residual disease postneoadjuvant (chemo)radiation, especially in patients who are not suitable for or do not wish to have surgery. Its role has mostly been studied to date in low- to intermediate-risk patients. We have now evaluated the utility of CXB boost in high-risk rectal cancers after their tumors have been significantly downstaged by neoadjuvant (chemo)radiation. MATERIALS AND METHODS: Oncological outcomes and treatment tolerability were evaluated in 328 patients based on rectal cancer treatment risk stratification: low-/intermediate-risk (cT1-3ab, N0-1, M0, no extramural venous invasion, mesorectal fascia involvement >1 mm) and high-risk (cT3cd-4/N2, M0, mesorectal fascia ≤1 mm, and/or extramural venous invasion positive). RESULTS: With a median follow-up of 33 (IQR, 15-54) months and a median age of 73 (IQR, 62-80) years, no significant differences were found between low/intermediate and high-risk groups in clinical complete response (78% vs. 73%, P = .32), local regrowth (16.6% vs. 22.4%, P = .41), nodal (1.8% vs. 5.8%, P = .051) or regional (1.3% vs. 2.9%, P = .33) relapse, or postradiation toxicities (P = .16). However, the high-risk group had a higher distant relapse rate (21.2% vs. 10.7%, P = .01), with no significant differences in 3-year organ preservation (80% vs. 87%, P = .25), 5-year disease-free survival (62% vs. 64%, P = .46), or overall survival (67% vs. 64%, P = .88). Longer treatment time, treatment gap >24 weeks between therapies, and administration of a higher than standard CXB dose were newly identified factors that negatively impacted outcomes. CONCLUSIONS: High-risk patients with rectal cancer treated with CXB boost had more distant relapses, but comparable locoregional tumor control, organ preservation, disease-free survival, and overall survival to lower risk patients, with acceptable toxicities. CXB boost is, therefore, a viable option for selected high-risk patients with rectal cancer. Timely reassessment, prompt referral, and CXB dose optimization are crucial for improving outcomes.
引用
- Than NW, Pritchard DM, Hughes DM, et al. Contact X-ray Brachytherapy as a Boost Therapy After Neoadjuvant (Chemo)Radiation in High-Risk Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39674328. doi:10.1016/j.ijrobp.2024.11.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。